The CELx HSP test measures HER2-related signaling in live breast cancer cells in real-time by evaluating the difference between agonist (ligand/growth factor)-induced signals in the absence or presence of a HER2 dimerization antagonist over a 4-hour duration [11]. Here, ERBB2 is linked to breast carcinoma.